Clinicopathologic challenge

[1]  S. Tyring,et al.  Thalidomide: dermatological indications, mechanisms of action and side‐effects , 2005, The British journal of dermatology.

[2]  A. Komiyama,et al.  Thalidomide therapy for juvenile-onset entero-Behçet disease. , 2003, The Journal of pediatrics.

[3]  M. G. Araújo,et al.  Hepatic involvement in lepromatous leprosy. , 2002, Leprosy review.

[4]  G Muller,et al.  Thalidomide as an emerging immunotherapeutic agent. , 1999, Immunology today.

[5]  G. Kaplan,et al.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes , 1991, The Journal of experimental medicine.

[6]  B. Das,et al.  Hepatic morphology in reactional states of leprosy. , 1989, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[7]  J. Sheskin.  The Treatment of Lepra Reaction In Lepromatous Leprosy , 1980, International journal of dermatology.

[8]  J. H. Pettit.  Erythema nodosum leprosum. , 1967, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.